NEUROBO PHARMACEUTICALS INC (NRBO) Stock Price, Quote, News and Overview
NASDAQ:NRBO - Nasdaq - US64132R4048 - Common Stock - Currency: USD
NRBO Quote, Performance and Key Statistics
NASDAQ:NRBO (11/27/2024, 8:56:43 PM)
2.36
+0.01 (+0.43%)
The current stock price of NRBO is 2.36 USD. In the past month the price decreased by -10.94%. In the past year, price decreased by -34.43%.
NRBO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.77 | 322.91B | ||
| AMGN | AMGEN INC | 13.1 | 146.19B | ||
| GILD | GILEAD SCIENCES INC | 13.79 | 132.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.58B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.47 | 64.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.59B | ||
| ARGX | ARGENX SE - ADR | 99.05 | 35.50B | ||
| ONC | BEIGENE LTD-ADR | 5.93 | 25.74B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 20.73B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.14B | ||
| BIIB | BIOGEN INC | 7.98 | 18.51B |
Related stock screener links
About NRBO
Company Profile
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2016-08-05. The company is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and T2DM. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, and peptide YY. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is to be administered once weekly subcutaneously. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure.
Company Info
NEUROBO PHARMACEUTICALS INC
545 Concord Avenue, Suite 210
Cambridge MASSACHUSETTS 02116 US
CEO: Richard Kang
Employees: 8
Phone: 18577029600
NEUROBO PHARMACEUTICALS INC / NRBO FAQ
What is the stock price of NEUROBO PHARMACEUTICALS INC today?
The current stock price of NRBO is 2.36 USD. The price increased by 0.43% in the last trading session.
What is the ticker symbol for NEUROBO PHARMACEUTICALS INC stock?
The exchange symbol of NEUROBO PHARMACEUTICALS INC is NRBO and it is listed on the Nasdaq exchange.
On which exchange is NRBO stock listed?
NRBO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEUROBO PHARMACEUTICALS INC stock?
8 analysts have analysed NRBO and the average price target is 27.2 USD. This implies a price increase of 1052.54% is expected in the next year compared to the current price of 2.36. Check the NEUROBO PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEUROBO PHARMACEUTICALS INC worth?
NEUROBO PHARMACEUTICALS INC (NRBO) has a market capitalization of 20.34M USD. This makes NRBO a Nano Cap stock.
How many employees does NEUROBO PHARMACEUTICALS INC have?
NEUROBO PHARMACEUTICALS INC (NRBO) currently has 8 employees.
What are the support and resistance levels for NEUROBO PHARMACEUTICALS INC (NRBO) stock?
NEUROBO PHARMACEUTICALS INC (NRBO) has a resistance level at 2.41. Check the full technical report for a detailed analysis of NRBO support and resistance levels.
Should I buy NEUROBO PHARMACEUTICALS INC (NRBO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NRBO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NRBO, evaluating the profitability, health, valuation and growth aspects
- NEUROBO PHARMACEUTICALS INC (NRBO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEUROBO PHARMACEUTICALS INC (NRBO) Sales and EPS estimates to see what analysts future expectations are.
- NEUROBO PHARMACEUTICALS INC (NRBO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEUROBO PHARMACEUTICALS INC (NRBO) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEUROBO PHARMACEUTICALS INC (NRBO) Stock Chart to make your own analysis
- NEUROBO PHARMACEUTICALS INC (NRBO) Latest news and press-releases to stay up to date.
Does NEUROBO PHARMACEUTICALS INC (NRBO) stock pay dividends?
NRBO does not pay a dividend.
What is the Price/Earnings (PE) ratio of NEUROBO PHARMACEUTICALS INC (NRBO)?
NEUROBO PHARMACEUTICALS INC (NRBO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6).
NRBO Technical Analysis
NRBO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NRBO. NRBO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NRBO Financial Highlights
Over the last trailing twelve months NRBO reported a non-GAAP Earnings per Share(EPS) of -6. The EPS increased by 62.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -125.23% | ||
| ROE | -214.1% | ||
| Debt/Equity | 0 |
NRBO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to NRBO. The Buy consensus is the average rating of analysts ratings from 8 analysts.